• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Spain Geographic Atrophy (GA) Market

    ID: MRFR/HC/49916-HCR
    200 Pages
    Garvit Vyas
    September 2025

    Spain Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography) and By Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Spain Geographic Atrophy (GA) Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    Spain Geographic Atrophy (GA) Market Summary

    The Spain Geographic Atrophy market is projected to experience substantial growth, reaching 665 million USD by 2035.

    Key Market Trends & Highlights

    Spain Geographic Atrophy GA Key Trends and Highlights

    • The market valuation for Geographic Atrophy in Spain is estimated at 323.6 million USD in 2024.
    • From 2025 to 2035, the market is expected to grow at a compound annual growth rate of 6.77%.
    • By 2035, the market is anticipated to expand to 665 million USD, indicating robust growth potential.
    • Growing adoption of advanced diagnostic technologies due to increasing prevalence of age-related macular degeneration is a major market driver.

    Market Size & Forecast

    2024 Market Size 323.6 (USD Million)
    2035 Market Size 665 (USD Million)
    CAGR (2025-2035) 6.77%

    Major Players

    HoffmannLa Roche, MeiraGTx, Horizon Therapeutics, Apellis Pharmaceuticals, Bayer AG, Alder BioPharmaceuticals, Novartis, EyePoint Pharmaceuticals, Visus Therapeutics, Amgen, AGTC, Genentech, Regeneron Pharmaceuticals, Otonomy, Alcon

    Spain Geographic Atrophy (GA) Market Trends

    The landscape of the Geographic Atrophy (GA) market in Spain is significantly influenced by several key market drivers. One of the primary drivers is the increasing prevalence of age-related macular degeneration (AMD), which has been a growing concern as Spain has one of the oldest populations in Europe. As citizens age, the demand for effective treatments and management options for GA is rising, creating a critical need for advancements in healthcare solutions.

    This growing demographic trend presents opportunities for pharmaceutical companies to expand their research and development efforts, particularly in personalized medicine approaches and innovative therapies tailored for the Spanish population. In recent times, there has been a noticeable shift towards digital health technologies and telemedicine in Spain, driven by the COVID-19 pandemic. This has enhanced patient access to healthcare services and monitoring, including specialized consultation for visual impairments associated with GA. The integration of these technologies not only improves patient convenience but also enables more effective management of GA by allowing for remote monitoring and timely interventions.

    Additionally, increased awareness about eye health and preventive care among the Spanish population has emerged. Educational initiatives by health organizations and local governments aim to inform citizens about the risks of AMD and the importance of regular eye screenings. This trend highlights an opportunity for stakeholders in the GA market to engage in awareness campaigns that promote early diagnosis and proactive management, thus improving patient outcomes. Furthermore, collaborations among healthcare professionals, research institutions, and industry players are fostering innovative solutions to address GA, shaping a dynamic environment for growth and development in Spain’s healthcare landscape.

    Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Spain Geographic Atrophy (GA) Market Drivers

    Market Segment Insights

    Get more detailed insights about Spain Geographic Atrophy (GA) Market

    Regional Insights

    Key Players and Competitive Insights

    The Spain Geographic Atrophy (GA) Market is characterized by its competitive landscape that is shaping treatment options for patients suffering from this degenerative eye condition. Geographic Atrophy, often associated with age-related macular degeneration, is a growing concern among healthcare providers and patients alike. In Spain, the market dynamics are influenced by advancements in biotechnology, increased investments in research and development, and rising awareness regarding the disease. The competitive insights reveal that companies are focusing on developing innovative treatment strategies, including gene therapies and novel drug formulations, to address the unmet medical needs of patients.

    Collaboration with healthcare institutions, strategic alliances, and robust clinical trial programs also play significant roles in shaping the competitive framework within the market, leading to diverse approaches in the management of Geographic Atrophy.HoffmannLa Roche has a noteworthy presence in the Spain Geographic Atrophy Market, leveraging its extensive expertise in ophthalmology and related therapeutics. The company is known for its innovative approach to treatment, focusing on evidence-based solutions that are tailored to the specific needs of patients in the region. HoffmannLa Roche benefits from a strong reputation for quality and reliability, which enhances its competitive advantage in Spain.

    Its research initiatives are often underscored by collaborations with leading scientific institutions and hospitals, resulting in a portfolio of products that are well-aligned with the latest advancements in medical science. Additionally, the company is adept at navigating regulatory frameworks in Spain, which allows for timely delivery of their treatments to patients and strengthens their overall market position. MeiraGTx has emerged as a significant player in the Spain Geographic Atrophy Market, focusing on gene therapy as a transformative approach to treating this condition.

    The company is dedicated to developing innovative solutions that address the underlying causes of Geographic Atrophy, and its key products reflect a commitment to cutting-edge research in the field of gene therapy. MeiraGTx's strengths lie in its strong technical capabilities and a solid pipeline of therapeutics that are currently undergoing clinical trials in the Spanish market. The company is actively engaged in fostering partnerships and collaborations that enhance its research efforts. By leveraging strategic mergers and acquisitions, MeiraGTx is expanding its market presence in Spain, ensuring a competitive edge in pioneering new treatment modalities.

    Its focus on bringing advanced therapies to patients aligns with the growing demand for specialized care in the region, making it a noteworthy contender in the geographic atrophy landscape.

    Key Companies in the Spain Geographic Atrophy (GA) Market market include

    Industry Developments

    In recent months, the Spain Geographic Atrophy GA Market has seen significant developments, particularly regarding innovative treatments from major companies. HoffmannLa Roche has been advancing its portfolio targeted at retinal diseases, while Apellis Pharmaceuticals continues to make strides with their complement-inhibition therapy, which shows promise for GA treatment. Bayer AG has been focusing on partnerships and enhancing its research capacity in eye care, aiming to launch new therapies by 2024.

    Market valuation for key players like Novartis and Regeneron Pharmaceuticals has risen as they expand their Research and Development efforts in Spain, signaling growing investor confidence and interest in GA therapies. In terms of mergers and acquisitions, no recent information has surfaced related specifically to the mentioned companies within Spain's GA market. Over the last 2-3 years, significant advances in clinical trials have occurred, highlighting a shift towards personalized medicine in the treatment of GA.

    This innovative approach fosters hopes of improved patient outcomes and engages multiple stakeholders in the healthcare sector, including regulatory bodies and clinical research organizations, indicating a positive future trajectory for the GA market in Spain.

    Market Segmentation

    Outlook

    • Late-Stage
    • Phase II
    • Phase I
    • Pre-Clinical Stage
    • Discovery Candidates
    •  

    Geographic Atrophy GA Market Age Group Outlook

    • Above 60 Years
    • Above 75 Years

    Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Outlook

    • Late-Stage
    • Phase II
    • Phase I
    • Pre-Clinical Stage
    • Discovery Candidates
    •  

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 323.63(USD Million)
    MARKET SIZE 2024 333.75(USD Million)
    MARKET SIZE 2035 665.0(USD Million)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 6.468% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Million
    KEY COMPANIES PROFILED HoffmannLa Roche, MeiraGTx, Horizon Therapeutics, Apellis Pharmaceuticals, Bayer AG, Alder BioPharmaceuticals, Novartis, EyePoint Pharmaceuticals, Visus Therapeutics, Amgen, AGTC, Genentech, Regeneron Pharmaceuticals, Otonomy, Alcon
    SEGMENTS COVERED Age Group, Diagnosis, Therapeutic Agents Clinical Phase
    KEY MARKET OPPORTUNITIES Aging population increasing prevalence, Innovative treatment development potential, Rising awareness and education initiatives, Advancements in diagnostic technologies, Increased funding for GA research
    KEY MARKET DYNAMICS aging population, increasing prevalence rates, rising healthcare expenditure, advancements in treatment options, growing awareness and diagnosis
    COUNTRIES COVERED Spain

    Market Highlights

    Author
    Garvit Vyas
    Analyst

    Explore the profile of Garvit Vyas, one of our esteemed authors at Market Research Future, and access their expert research contributions in the field of market research and industry analysis

    Leave a Comment

    FAQs

    What is the projected market size of the Spain Geographic Atrophy GA Market in 2024?

    The projected market size of the Spain Geographic Atrophy GA Market in 2024 is 333.75 million USD.

    What is the expected market size of the Spain Geographic Atrophy GA Market by 2035?

    The market is expected to grow to 665.0 million USD by 2035.

    What is the Compound Annual Growth Rate (CAGR) for the Spain Geographic Atrophy GA Market from 2025 to 2035?

    The CAGR for the Spain Geographic Atrophy GA Market from 2025 to 2035 is anticipated to be 6.468%.

    Which age group represents the largest portion of the Spain Geographic Atrophy GA Market?

    The age group above 60 years represents the largest portion, valued at 200.0 million USD in 2024.

    What is the market value for the age group above 75 years in 2024?

    The market value for the age group above 75 years in 2024 is 133.75 million USD.

    What will be the market value for the age group above 60 years by 2035?

    The market value for the age group above 60 years is expected to reach 400.0 million USD by 2035.

    Who are the key players in the Spain Geographic Atrophy GA Market?

    Key players in the market include HoffmannLa Roche, Bayer AG, and Regeneron Pharmaceuticals among others.

    What is the anticipated market value for the age group above 75 years by 2035?

    The anticipated market value for the age group above 75 years by 2035 is 265.0 million USD.

    What are some emerging trends in the Spain Geographic Atrophy GA Market?

    Emerging trends include increased investments in research and development and innovative treatment options.

    How have the dynamics of the Spain Geographic Atrophy GA Market changed recently?

    The dynamics of the market have changed with an increasing population aging and rising awareness regarding eye health.

    1. EXECUTIVE SUMMARY
    2. Market Overview
    3. Key Findings
    4. Market Segmentation
    5. Competitive Landscape
    6. Challenges and Opportunities
    7. Future Outlook
    8. MARKET INTRODUCTION
    9. Definition
    10. Scope of the study
    11. Research Objective
    12. Assumption
    13. Limitations
    14. RESEARCH METHODOLOGY
    15. Overview
    16. Data Mining
    17. Secondary Research
    18. Primary Research
    19. Primary Interviews and Information Gathering Process
    20. Breakdown of Primary Respondents
    21. Forecasting Model
    22. Market Size Estimation
    23. Bottom-Up Approach
    24. Top-Down Approach
    25. Data Triangulation
    26. Validation
    27. MARKET DYNAMICS
    28. Overview
    29. Drivers
    30. Restraints
    31. Opportunities
    32. MARKET FACTOR ANALYSIS
    33. Value chain Analysis
    34. Porter's Five Forces Analysis
    35. Bargaining Power of Suppliers
    36. Bargaining Power of Buyers
    37. Threat of New Entrants
    38. Threat of Substitutes
    39. Intensity of Rivalry
    40. COVID-19 Impact Analysis
    41. Market Impact Analysis
    42. Regional Impact
    43. Opportunity and Threat Analysis
    44. Spain Geographic Atrophy GA Market, BY Age Group (USD Million)
    45. Above 60 Years
    46. Above 75 Years
    47. Spain Geographic Atrophy GA Market, BY Diagnosis (USD Million)
    48. Fundus Autofluorescence
    49. Optical Coherence Tomography Angiography
    50. Multifocal Electroretinography
    51. Spain Geographic Atrophy GA Market, BY Therapeutic Agents Clinical Phase (USD Million)
    52. Late-Stage
    53. Phase II
    54. Phase I
    55. Pre-Clinical Stage
    56. Discovery Candidates
    57. Competitive Landscape
    58. Overview
    59. Competitive Analysis
    60. Market share Analysis
    61. Major Growth Strategy in the Geographic Atrophy GA Market
    62. Competitive Benchmarking
    63. Leading Players in Terms of Number of Developments in the Geographic Atrophy GA Market
    64. Key developments and growth strategies
    65. New Product Launch/Service Deployment
    66. Merger & Acquisitions
    67. Joint Ventures
    68. Major Players Financial Matrix
    69. Sales and Operating Income
    70. Major Players R&D Expenditure. 2023
    71. Company Profiles
    72. HoffmannLa Roche
    73. Financial Overview
    74. Products Offered
    75. Key Developments
    76. SWOT Analysis
    77. Key Strategies
    78. MeiraGTx
    79. Financial Overview
    80. Products Offered
    81. Key Developments
    82. SWOT Analysis
    83. Key Strategies
    84. Horizon Therapeutics
    85. Financial Overview
    86. Products Offered
    87. Key Developments
    88. SWOT Analysis
    89. Key Strategies
    90. Apellis Pharmaceuticals
    91. Financial Overview
    92. Products Offered
    93. Key Developments
    94. SWOT Analysis
    95. Key Strategies
    96. Bayer AG
    97. Financial Overview
    98. Products Offered
    99. Key Developments
    100. SWOT Analysis
    101. Key Strategies
    102. Alder BioPharmaceuticals
    103. Financial Overview
    104. Products Offered
    105. Key Developments
    106. SWOT Analysis
    107. Key Strategies
    108. Novartis
    109. Financial Overview
    110. Products Offered
    111. Key Developments
    112. SWOT Analysis
    113. Key Strategies
    114. EyePoint Pharmaceuticals
    115. Financial Overview
    116. Products Offered
    117. Key Developments
    118. SWOT Analysis
    119. Key Strategies
    120. Visus Therapeutics
    121. Financial Overview
    122. Products Offered
    123. Key Developments
    124. SWOT Analysis
    125. Key Strategies
    126. Amgen
    127. Financial Overview
    128. Products Offered
    129. Key Developments
    130. SWOT Analysis
    131. Key Strategies
    132. AGTC
    133. Financial Overview
    134. Products Offered
    135. Key Developments
    136. SWOT Analysis
    137. Key Strategies
    138. Genentech
    139. Financial Overview
    140. Products Offered
    141. Key Developments
    142. SWOT Analysis
    143. Key Strategies
    144. Regeneron Pharmaceuticals
    145. Financial Overview
    146. Products Offered
    147. Key Developments
    148. SWOT Analysis
    149. Key Strategies
    150. Otonomy
    151. Financial Overview
    152. Products Offered
    153. Key Developments
    154. SWOT Analysis
    155. Key Strategies
    156. Alcon
    157. Financial Overview
    158. Products Offered
    159. Key Developments
    160. SWOT Analysis
    161. Key Strategies
    162. References
    163. Related Reports
    164. Spain Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY AGE GROUP, 2019-2035 (USD Billions)
    165. Spain Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY DIAGNOSIS, 2019-2035 (USD Billions)
    166. Spain Geographic Atrophy GA Market SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2019-2035 (USD Billions)
    167. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    168. ACQUISITION/PARTNERSHIP
    169. MARKET SYNOPSIS
    170. SPAIN GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY AGE GROUP
    171. SPAIN GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY DIAGNOSIS
    172. SPAIN GEOGRAPHIC ATROPHY GA MARKET ANALYSIS BY THERAPEUTIC AGENTS CLINICAL PHASE
    173. KEY BUYING CRITERIA OF GEOGRAPHIC ATROPHY GA MARKET
    174. RESEARCH PROCESS OF MRFR
    175. DRO ANALYSIS OF GEOGRAPHIC ATROPHY GA MARKET
    176. DRIVERS IMPACT ANALYSIS: GEOGRAPHIC ATROPHY GA MARKET
    177. RESTRAINTS IMPACT ANALYSIS: GEOGRAPHIC ATROPHY GA MARKET
    178. SUPPLY / VALUE CHAIN: GEOGRAPHIC ATROPHY GA MARKET
    179. GEOGRAPHIC ATROPHY GA MARKET, BY AGE GROUP, 2025 (% SHARE)
    180. GEOGRAPHIC ATROPHY GA MARKET, BY AGE GROUP, 2019 TO 2035 (USD Billions)
    181. GEOGRAPHIC ATROPHY GA MARKET, BY DIAGNOSIS, 2025 (% SHARE)
    182. GEOGRAPHIC ATROPHY GA MARKET, BY DIAGNOSIS, 2019 TO 2035 (USD Billions)
    183. GEOGRAPHIC ATROPHY GA MARKET, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2025 (% SHARE)
    184. GEOGRAPHIC ATROPHY GA MARKET, BY THERAPEUTIC AGENTS CLINICAL PHASE, 2019 TO 2035 (USD Billions)
    185. BENCHMARKING OF MAJOR COMPETITORS

    Spain Geographic Atrophy GA Market Segmentation

     

    • Geographic Atrophy GA Market By Age Group (USD Million, 2019-2035)

      • Above 60 Years
      • Above 75 Years

     

    • Geographic Atrophy GA Market By Diagnosis (USD Million, 2019-2035)

      • Fundus Autofluorescence
      • Optical Coherence Tomography Angiography
      • Multifocal Electroretinography

     

    • Geographic Atrophy GA Market By Therapeutic Agents Clinical Phase (USD Million, 2019-2035)

      • Late-Stage
      • Phase II
      • Phase I
      • Pre-Clinical Stage
      • Discovery Candidates

     

     

     

     

     

     

    Report Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials